Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.
Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.
Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain.
SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.
Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities.
The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation.
The Center for Synovial Sarcoma Biology and Therapeutics
Reversing Oncogenic BAF Complex Structure & Function: New Therapeutic Approaches
Cancer-Specific Targeting and Function of Mammalian SWI/SNF (BAF) Chromatin Remodeling Complexes
A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.
The nucleosome acidic patch and H2A ubiquitination underlie mSWI/SNF recruitment in synovial sarcoma.
Author Correction: The nucleosome acidic patch and H2A ubiquitination underlie mSWI/SNF recruitment in synovial sarcoma.
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.